Clinical trials
Trials joined to the biology they test and the companies that run them
Coverage
- 251,000+ trials from ClinicalTrials.gov, including every trial with a drug intervention registered since 2020.
- Free text turned into structured fields: normalized sponsors and conditions, structured eligibility, categorized stop reasons, and typed trial arms.
- 11.6M+ adverse events, normalized and connected onward to MedDRA, UMLS, SNOMED CT, MeSH, and ICD-10.
Where it connects
Trial record
NCT03574597
Drugs
Each arm's intervention, resolved to a drug record
experimental
titleSemaglutide
drugbank_idDB13928
placebo_comparator
titlePlacebo (semaglutide)
drugbank_idnull
Targets
The mechanism, reached through the intervention drug
nameGlucagon-like peptide 1 receptor
biodb_idBE0000857
typeTargetBond
agonisttrue
pharmacological_actionyes
+4 more proteins
Diseases
The condition studied, connected to other ontologies
titleObesity
drugbank_idDBCOND0015947
icd10c/E66
meddrapt/10029883
mesht/T029022
snomedc/414916001
+1 more condition
Companies
The sponsor as filed, and the parent that owns it today
trial_idNCT03574597
sponsors.titleNovo Nordisk A/S
companies.nameNovo Nordisk
1,560 trials roll up to this parent, 98 of them through 8 absorbed companies
Zoom in
| identifier | status | why_stopped | category | safety_efficacy_concern |
|---|---|---|---|---|
| NCT03263091 | terminated | Study did not meet its primary efficacy endpoint. | Efficacy | 1 |
| NCT02412631 | terminated | Lorcaserin removed from market | Drug Recall | 1 |
| NCT00873002 | terminated | Dose Limiting Toxicity | MTD was Reached | 1 |
| NCT05893069 | suspended | FDA withdrew approval of the study product | Drug Recall | 1 |
| NCT03147690 | terminated | Stopped for futility | Futility | 0 |
| NCT02321319 | terminated | Business decision - product discontinued | Business Decision | 0 |
| NCT04080908 | terminated | Unable to meet enrollment goals. | Recruitment | 0 |
| trial_id | gender | gender_based | min_age | max_age | healthy_volunteers |
|---|---|---|---|---|---|
| NCT03574597 | All | 0 | 45 Years | [] | No |
| NCT03113773 | All | 0 | 18 Years | 85 Years | No |
| NCT06724900 | Female | 1 | 18 Years | 75 Years | Accepts Healthy Volunteers |
| NCT04878731 | Male | 1 | 18 Years | 74 Years | No |
| NCT02851797 | Male | 1 | 6 Years | 17 Years | No |
| NCT05099484 | Female | 1 | 18 Years | 45 Years | [] |
| outcome_type | title | time_frame |
|---|---|---|
| primary | Subjects Included in the Composite Endpoint of CV Death, Hospitalization for Heart Failure or Urgent Heart Failure Visit | Up to 27.8 months. |
| secondary | Subjects Included in the Composite Endpoint of ≥50% Sustained Decline in eGFR | Up to 27.8 months. |
| secondary | Events Included in the Composite Endpoint of Recurrent Hospitalization for Heart Failure | Up to 27.8 months. |
| secondary | Change From Baseline in the KCCQ Total Symptom Score | Baseline and 8 months or death before 8 months |
| secondary | Subjects Included in the Composite Endpoint of CV Death or Hospitalization for Heart Failure | Up to 27.8 months. |
| secondary | Subjects Included in the Endpoint of All-cause Mortality. | Up to 27.8 months. |
| arm_group.kind | event_type | event_term | condition_id | num_affected |
|---|---|---|---|---|
| experimental | serious | Acute myocardial infarction | DBCOND0032772 | 209 |
| placebo_comparator | serious | Acute myocardial infarction | DBCOND0032772 | 293 |
| experimental | serious | Cholelithiasis | DBCOND0000937 | 44 |
| placebo_comparator | serious | Cholelithiasis | DBCOND0000937 | 31 |
| experimental | other | Nausea | DBCOND0010699 | 1592 |
| placebo_comparator | other | Nausea | DBCOND0010699 | 337 |
| experimental | other | Diarrhoea | DBCOND0126047 | 933 |
| placebo_comparator | other | Diarrhoea | DBCOND0126047 | 353 |
+3,528 more adverse events on this trial
| facility_name | country | zip | status |
|---|---|---|---|
| Radboudumc | Netherlands | 6525 GA | Recruiting |
| Centro Cardiologico Monzino | Italy | 20138 | Recruiting |
| Futuremeds-Newcastle | United Kingdom | NE6 1SG | Recruiting |
| Changzhou Second People's Hospital | China | 213000 | Recruiting |
| Central India Cardiology and Research Institute | India | 440015 | Recruiting |
| Medical Center Salutem | Ukraine | 21001 | Recruiting |
| CEINV Salud | Mexico | 64020 | Not yet recruiting |
555 sites across 38 countries on this trial
Questions it answers
- Who is running trials against a given mechanism, and at what phase? Landscape and whitespace analysis
- Has this target shown human proof of concept, and on which outcome measures? Target diligence
- Why did trials in this indication stop, and was safety one of the reasons? Risk assessment
All figures pulled as of November 2026.